118183-92-9

Basic information

• Product Name: 3-(4-BROMOPHENYL)-5-METHYL-1,2,4-OXADIAZOLE
• Synonyms: 3-(4-BROMOPHENYL)-5-METHYL-1,2,4-OXADIAZOLE;4-(5-Methyl-1,2,4-oxadiazol-3-yl)bromobenzene;1-Bromo-4-(5-methyl-1,2,4-oxadiazol-3-yl)benzene
• CAS NO: 118183-92-9
• Molecular Formula: C₉H₇BrN₂O
• Molecular Weight: 239.07
• Product Categories: blocks;Bromides;Heterocycles
• Mol File: 118183-92-9.mol
• Article Data: 13

Chemical Properties

• Melting Point: 98 °C
• Boiling Point: 327.9 ºC at 760 mmHg
• Flash Point: 152.1 ºC
• Appearance: White Solid
• Density: 1.528 g/cm³
• Vapor Pressure: 0.000375mmHg at 25°C
• Refractive Index: 1.577
• Storage Temp.: 2-8°C
• PKA: -0.50±0.25(Predicted)
• CAS DataBase Reference: 3-(4-BROMOPHENYL)-5-METHYL-1,2,4-OXADIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-BROMOPHENYL)-5-METHYL-1,2,4-OXADIAZOLE(118183-92-9)
• EPA Substance Registry System: 3-(4-BROMOPHENYL)-5-METHYL-1,2,4-OXADIAZOLE(118183-92-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• WGK Germany: 3
• Hazardous Substances Data: 118183-92-9(Hazardous Substances Data)

Usage

General Description

3-(4-Bromophenyl)-5-methyl-1,2,4-oxadiazole is a chemical compound that belongs to the oxadiazole family. It is an organic compound with the molecular formula C9H7BrN2O and has a molar mass of 228.07 g/mol. 3-(4-BROMOPHENYL)-5-METHYL-1,2,4-OXADIAZOLE is characterized by the presence of a 1,2,4-oxadiazole ring, which makes it a potential candidate for various biological and pharmaceutical applications. It has been studied for its potential use in the development of new drugs, particularly in the field of medicinal chemistry and drug discovery. The bromophenyl and methyl groups in its structure also provide opportunities for further chemical modification and optimization to enhance its properties and potential applications. Overall, 3-(4-bromophenyl)-5-methyl-1,2,4-oxadiazole is a versatile chemical compound with potential utility in various fields, including pharmaceuticals and material science.

InChI:InChI=1/C9H7BrN2O/c1-6-11-9(12-13-6)7-2-4-8(10)5-3-7/h2-5H,1H3

Upstream product

• 19227-14-6 p-bromobenzamidoxime 
• 108-24-7 acetic anhydride 
• 19227-14-6 (Z)-4-bromo-N′-hydroxybenzimidamide 
• 76670-28-5 C₉H₉BrN₂O₂ 
• 25062-46-8 4-bromobenzaldehyde Oxime 
• 75-05-8 acetonitrile 
• 2033-24-1 cycl-isopropylidene malonate 
• 623-00-7 4-bromobenzenecarbonitrile 
• 19227-14-6 4-bromo-N-hydroxybenzenecarboximidamide 
• 18871-66-4 N,N-dimethylacetamide dimethyl acetal 
• 75-36-5 acetyl chloride 

Downstream Products

• 845616-96-8 4-[4-(5-Methyl-[1,2,4]oxadiazol-3-yl)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 873934-00-0 4'-(5-methyl-[1,2,4]oxadiazol-3-yl)-biphenyl-4-carbaldehyde 

Relevant articles and documents

Cobalt(III)-Catalyzed Oxadiazole-Directed C-H Activation for the Synthesis of 1-Aminoisoquinolines

Aromatic heterocycles have been identified as effective directing groups (DGs) in C-H functionalization but can be retained as undesired bulky substituents in the final products. Herein, we report a Co(III)-catalyzed 1-aminoisoquinoline synthesis strategy based on oxadiazole-directed aromatic C-H coupling with alkynes and a subsequent redox-neutral C-N cyclization reaction. This labile N-O bond-based protocol has allowed the toleration of a broad range of functional groups.

NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention provides a novel phenylpropionic acid derivative and a PPAR-γ modulator comprising the same as an active ingredient. The phenylpropionic acid derivative of the present invention has modulatory action on function of PPAR-γ and then exhibits hypoglycemic, hypolipidemic and insulin resistance-reducing effects on PPAR-mediated diseases or disorders. Therefore, the present invention is prophylactically or therapeutically effective for diabetes and metabolic diseases.

Histamine-3 receptor antagonist

This invention is directed to a compound of the formula I as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treat